Drug intelligence / Profile preview

Alminoprofen

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Alminoprofen is a non-steroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class, structurally related to ibuprofen but with an isobutyl group replaced by a (2-methylprop-2-en-1-yl)amino group. It is primarily used for the treatment of inflammatory and rheumatic disorders. Alminoprofen acts as an inhibitor of both cyclooxygenase 2 (COX‑2) and secretory phospholipase A2 (sPLA₂), reducing inflammation and pain while minimizing gastrointestinal side effects compared to some other NSAIDs. Its mechanism involves selective inhibition of COX‑2, antiphospholipase A₂ activity, and general non-narcotic analgesic effects[1][3][6].

Brand names: Minalfene
Other names: 2-(4-((2-Methylallyl)amino)phenyl)propanoic acidAlminoprofenAlminoprofene

Targets

PLA2 (Phospholipase A2 group IID)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Alminoprofen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alminoprofen.

Explore the full profile